Wavelength-Pharmaceuticals-Insert
X

Find Drugs for Infections and Infectious Diseases in Phase I/ Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: U.K Governement

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 20, 2020

            Details:

            The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. The BNT162 vaccine candidates are undergoing clinical studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT162

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 05, 2020

            Details:

            The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates, under BNT162 vaccine program, evaluated in a single, continuous study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Starr mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Lunar-Cov19

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Israeli Ministry of Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 23, 2020

            Details:

            Under the terms of the agreement, Arcturus will supply the Company’s COVID-19 vaccine candidate, LUNAR-COV19 to Israeli Ministry of Health. The parties intend to finalize a comprehensive supply agreement within 30 days.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Starr mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Lunar-Cov19

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Duke-NUS Medical School

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2020

            Details:

            The healthy volunteer study will evaluate several dose levels of LUNAR-COV19 in up to 108 adults, including older adults. Follow-up will be conducted to evaluate safety, tolerability and the extent and duration of the humoral and cellular immune response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ad26.COV2-S

            Therapeutic Area: Infections and Infectious Diseases Product Name: JNJ-78436735

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            The company is on track to begin its early-stage human trial of the vaccine later this month, expected to begin in Belgium on July 22.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX‑CoV2373

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX‑CoV2373

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Operation Warp Speed

            Deal Size: $1,600.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 07, 2020

            Details:

            Under the terms of the agreement, Novavax will demonstrate it can rapidly stand up large-scale manufacturing and transition into ongoing production, including the capability to stockpile and distribute large quantities of NVX-CoV2373 when needed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rintatolimod,Interferon Alfa-2B

            Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Shionogi Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 06, 2020

            Details:

            Under the agreement, AIM will provide Ampligen samples, in order to get it tested as a potential adjuvant therapy for COVID-19, for various research projects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ad26.COV2-S

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Johnson & Johnson

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 06, 2020

            Details:

            Under the agreement, Emergent will begin providing large-scale drug substance manufacturing for Johnson & Johnson’s adenovirus-based COVID-19 vaccine in 2021, upon successful completion of the activities under the previously executed Technology Transfer Agreement.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodiumnitrite

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            NuvOx Pharma had data in several animal models showing that NanO2 restored oxygen levels in conditions of low oxygen caused by ARDS or acute lung injury.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AP-SA02

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $15.0 million Upfront Cash: Undisclosed

            Deal Type: Funding June 17, 2020

            Details:

            Armata will use the award to partially fund a Phase 1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia infections.

            PharmaCompass